Holen Sie sich die Stockscreener-App
0.3075
6.40%
0.0185
Handel nachbörslich:
.31
0.0025
+0.81%
IGC Pharma Inc Aktie (IGC) Neueste Nachrichten
Can IGC Pharma Inc. (IGS1) stock sustain institutional flowsStock Price Forecasts & Analyze Your Portfolio Risk in Seconds - bollywoodhelpline.com
IGC Pharma (IGC) Aligns Fiscal Year with Calendar Year - GuruFocus
IGC Pharma Aligns Fiscal Year with Calendar Year to Enhance U.S. Investor Transparency and Comparability - Finviz
IGC Pharma (NYSE American: IGC) prices direct 779,997-share stock sale - Stock Titan
IGC Pharma Announces Registered Direct Equity Offering Financing - TipRanks
IGC Pharma Signs Subscription Agreement With Certain Investors - TradingView — Track All Markets
How IGC Pharma Inc. (IGS1) stock expands through international markets2026 world cup usa national team round of 32 midfield engines high defensive line tactical prediction preview - ulpravda.ru
IGC Pharma Raises Capital to Advance IGC-AD1 Phase 2 Trial - BioSpace
IGC Pharma (NYSE American: IGC) plans $234K registered stock sale - Stock Titan
IGC Pharma (IGC) Secures Funding Through Share Sale - GuruFocus
Small biotech secures cash to keep its Alzheimer's trial moving - Stock Titan
IGC Pharma adjusts fiscal year-end to December 31 - MSN
IGC Pharma, Inc. (IGC) Reports Q4 Loss, Beats Revenue Estimates - MSN
IGC Pharma Adjusts Fiscal Year-End to December 31 - TipRanks
IGC Pharma (IGC) shifts fiscal year-end to December 31 with 9‑month transition - Stock Titan
IGC Pharma, Inc. Approves Change in the Fiscal Year-End from March 31 to December 31 - MarketScreener
IGC Pharma (IGC) Institutional Ownership 2026 - MarketBeat
IGC Pharma increases authorized shares to 600 million - MSN
Operating cash flow per share of IGC Pharma, Inc. – SWB:IGS1 - TradingView — Track All Markets
IGC Pharma Inc. (IGC) Stock Price | Live Quotes & Charts | AMEX - StocksToTrade
Would You Still Hold IGC Pharma Stock If It Fell Another 30%? - Trefis
IGC Pharma (FRA:IGS1) EV-to-OCF : -4.65 (As of Dec. 21, 2025) - GuruFocus
How IGC Pharma Inc. stock responds to policy changesWeekly Trend Summary & Long-Term Capital Growth Strategies - Улправда
IGC Pharma Secures New U.S. Patent as Pharmaceutical Cannabinoids Gain Regulatory Momentum - Big News Network.com
Will IGC Pharma Inc. stock outperform benchmarksInflation Watch & Verified Swing Trading Watchlists - Улправда
IGC Pharma Secures U.S. Patent for Innovative Stuttering Treatme - GuruFocus
What makes IGC Pharma Inc. stock appealing to growth investors2025 Trading Volume Trends & Accurate Buy Signal Notifications - DonanımHaber
How IGC Pharma Inc. stock benefits from strong dollarWeekly Trade Report & High Return Trade Opportunity Guides - DonanımHaber
Can IGC Pharma Inc. stock deliver strong Q4 earningsWeekly Investment Summary & Technical Buy Zone Confirmation - DonanımHaber
Why IGC Pharma Inc. stock remains stableJuly 2025 Selloffs & Low Risk Growth Stock Ideas - DonanımHaber
Aug Analyst Calls: How IGC Pharma Inc. (IGS1) stock expands through international markets2025 Pullback Review & Long-Term Growth Stock Strategies - Улправда
IGC Pharma Inc - Reuters
IGC Pharma comments on potential reclassification of cannabis - MSN
IGC Pharma Increases Authorized Shares to 600 Million - The Globe and Mail
IGC Pharma Positions as a Singular Beneficiary of Emerging Feder - GuruFocus
IGC Pharma (IGC) Advances in FDA-regulated Cannabinoid Drug Deve - GuruFocus
IGC Pharma Positions as a Singular Beneficiary of Emerging Federal Momentum Toward Schedule III Cann - pharmiweb.com
IGC Pharma Positions as a Singular Beneficiary of Emerging Federal Momentum Toward Schedule III Cannabinoid Medicines - Weatherford Democrat
IGC Pharma Inc IGC’s stock price falss traction on Thursday - uspostnews.com
It is Poised to be a Bull Market for IGC Pharma Inc (IGC) - setenews.com
IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q2 results. We believe more positive clinical data and progress in 2025/26 to be strong catalysts for stock. Raising P/T to $4.75." - Digital Journal
IGC Pharma : Announces Coverage Report by Ascendiant Capital Markets about the “Reports Q2 results. We believe more positive clinical data and progress in 2025/26 to be strong catalysts for stock. Raising P/T to $4.75.” - marketscreener.com
IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q2 results. We - pharmiweb.com
IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the - Big News Network.com
28.63%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):